Literature DB >> 23378636

Identification of CDCP1 as a hypoxia-inducible factor 2α (HIF-2α) target gene that is associated with survival in clear cell renal cell carcinoma patients.

Brooke M Emerling1, Cyril H Benes, George Poulogiannis, Eric L Bell, Kevin Courtney, Hui Liu, Rayman Choo-Wing, Gary Bellinger, Kazumi S Tsukazawa, Victoria Brown, Sabina Signoretti, Stephen P Soltoff, Lewis C Cantley.   

Abstract

CUB domain-containing protein 1 (CDCP1) is a transmembrane protein that is highly expressed in stem cells and frequently overexpressed and tyrosine-phosphorylated in cancer. CDCP1 promotes cancer cell metastasis. However, the mechanisms that regulate CDCP1 are not well-defined. Here we show that hypoxia induces CDCP1 expression and tyrosine phosphorylation in hypoxia-inducible factor (HIF)-2α-, but not HIF-1α-, dependent fashion. shRNA knockdown of CDCP1 impairs cancer cell migration under hypoxic conditions, whereas overexpression of HIF-2α promotes the growth of tumor xenografts in association with enhanced CDCP1 expression and tyrosine phosphorylation. Immunohistochemistry analysis of tissue microarray samples from tumors of patients with clear cell renal cell carcinoma shows that increased CDCP1 expression correlates with decreased overall survival. Together, these data support a critical role for CDCP1 as a unique HIF-2α target gene involved in the regulation of cancer metastasis, and suggest that CDCP1 is a biomarker and potential therapeutic target for metastatic cancers.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23378636      PMCID: PMC3587206          DOI: 10.1073/pnas.1222435110

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  34 in total

1.  A new mathematical model for relative quantification in real-time RT-PCR.

Authors:  M W Pfaffl
Journal:  Nucleic Acids Res       Date:  2001-05-01       Impact factor: 16.971

2.  Identification of a novel gene, CDCP1, overexpressed in human colorectal cancer.

Authors:  M Scherl-Mostageer; W Sommergruber; R Abseher; R Hauptmann; P Ambros; N Schweifer
Journal:  Oncogene       Date:  2001-07-19       Impact factor: 9.867

3.  A conserved family of prolyl-4-hydroxylases that modify HIF.

Authors:  R K Bruick; S L McKnight
Journal:  Science       Date:  2001-10-11       Impact factor: 47.728

4.  C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation.

Authors:  A C Epstein; J M Gleadle; L A McNeill; K S Hewitson; J O'Rourke; D R Mole; M Mukherji; E Metzen; M I Wilson; A Dhanda; Y M Tian; N Masson; D L Hamilton; P Jaakkola; R Barstead; J Hodgkin; P H Maxwell; C W Pugh; C J Schofield; P J Ratcliffe
Journal:  Cell       Date:  2001-10-05       Impact factor: 41.582

5.  HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing.

Authors:  M Ivan; K Kondo; H Yang; W Kim; J Valiando; M Ohh; A Salic; J M Asara; W S Lane; W G Kaelin
Journal:  Science       Date:  2001-04-05       Impact factor: 47.728

6.  Subtractive immunization using highly metastatic human tumor cells identifies SIMA135/CDCP1, a 135 kDa cell surface phosphorylated glycoprotein antigen.

Authors:  John D Hooper; Andries Zijlstra; Ronald T Aimes; Hongyan Liang; Gisela F Claassen; David Tarin; Jacqueline E Testa; James P Quigley
Journal:  Oncogene       Date:  2003-03-27       Impact factor: 9.867

7.  Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein.

Authors:  Keiichi Kondo; Jeff Klco; Eijiro Nakamura; Mirna Lechpammer; William G Kaelin
Journal:  Cancer Cell       Date:  2002-04       Impact factor: 31.743

8.  The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma.

Authors:  Jodi K Maranchie; James R Vasselli; Joseph Riss; Juan S Bonifacino; W Marston Linehan; Richard D Klausner
Journal:  Cancer Cell       Date:  2002-04       Impact factor: 31.743

Review 9.  Targeting HIF-1 for cancer therapy.

Authors:  Gregg L Semenza
Journal:  Nat Rev Cancer       Date:  2003-10       Impact factor: 60.716

10.  Genetic and functional studies implicate HIF1α as a 14q kidney cancer suppressor gene.

Authors:  Chuan Shen; Rameen Beroukhim; Steven E Schumacher; Jing Zhou; Michelle Chang; Sabina Signoretti; William G Kaelin
Journal:  Cancer Discov       Date:  2011-06-07       Impact factor: 39.397

View more
  23 in total

1.  CDCP1 cleavage is necessary for homodimerization-induced migration of triple-negative breast cancer.

Authors:  H J Wright; J Arulmoli; M Motazedi; L J Nelson; F S Heinemann; L A Flanagan; O V Razorenova
Journal:  Oncogene       Date:  2016-02-15       Impact factor: 9.867

2.  CDCP1 drives triple-negative breast cancer metastasis through reduction of lipid-droplet abundance and stimulation of fatty acid oxidation.

Authors:  Heather J Wright; Jue Hou; Binzhi Xu; Marvin Cortez; Eric O Potma; Bruce J Tromberg; Olga V Razorenova
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-24       Impact factor: 11.205

3.  Elevated CDCP1 predicts poor patient outcome and mediates ovarian clear cell carcinoma by promoting tumor spheroid formation, cell migration and chemoresistance.

Authors:  Y He; A C Wu; B S Harrington; C M Davies; S J Wallace; M N Adams; J S Palmer; D K Roche; B G Hollier; T F Westbrook; H Hamidi; G E Konecny; B Winterhoff; N P Chetty; A J Crandon; N B Oliveira; C M Shannon; A V Tinker; C B Gilks; J I Coward; J W Lumley; L C Perrin; J E Armes; J D Hooper
Journal:  Oncogene       Date:  2015-04-20       Impact factor: 9.867

4.  Theranostic Targeting of CUB Domain Containing Protein 1 (CDCP1) in Pancreatic Cancer.

Authors:  Anna Moroz; Yung-Hua Wang; Jeremy M Sharib; Junnian Wei; Ning Zhao; Yangjie Huang; Zhuo Chen; Alexander J Martinko; Jie Zhuo; Shion A Lim; Lydia H Zhang; Youngho Seo; Sean Carlin; Kevin K Leung; Eric A Collisson; Kimberly S Kirkwood; James A Wells; Michael J Evans
Journal:  Clin Cancer Res       Date:  2020-04-27       Impact factor: 12.531

5.  FBXL14 abolishes breast cancer progression by targeting CDCP1 for proteasomal degradation.

Authors:  Yan-Hong Cui; Hyeonmi Kim; Minyoung Lee; Joo Mi Yi; Rae-Kwon Kim; Nizam Uddin; Ki-Chun Yoo; Jae Hyeok Kang; Mi-Young Choi; Hyuk-Jin Cha; Ok-Seon Kwon; In-Hwa Bae; Min-Jung Kim; Neha Kaushik; Su-Jae Lee
Journal:  Oncogene       Date:  2018-07-04       Impact factor: 9.867

6.  miR-198 functions as a tumor suppressor in breast cancer by targeting CUB domain-containing protein 1.

Authors:  Yingbin Hu; Ziyuan Tang; Bonian Jiang; Juying Chen; Zhongpin Fu
Journal:  Oncol Lett       Date:  2017-02-02       Impact factor: 2.967

7.  CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null Disease.

Authors:  Ning Zhao; Shalini Chopra; Kai Trepka; Yung-Hua Wang; Sasank Sakhamuri; Nima Hooshdaran; Hyunjung Kim; Jie Zhou; Shion A Lim; Kevin K Leung; Emily A Egusa; Jun Zhu; Li Zhang; Adam Foye; Renuka Sriram; Emily Chan; Youngho Seo; Felix Y Feng; Eric J Small; Jonathan Chou; James A Wells; Rahul Aggarwal; Michael J Evans
Journal:  Clin Cancer Res       Date:  2022-07-15       Impact factor: 13.801

8.  HIF-2α regulates CDCP1 to promote PKCδ-mediated migration in hepatocellular carcinoma.

Authors:  Manqing Cao; Junrong Gao; Hongyuan Zhou; Jiafei Huang; Abin You; Zhigui Guo; Feng Fang; Wei Zhang; Tianqiang Song; Ti Zhang
Journal:  Tumour Biol       Date:  2015-08-26

9.  CDCP1 enhances Wnt signaling in colorectal cancer promoting nuclear localization of β-catenin and E-cadherin.

Authors:  Yaowu He; Claire M Davies; Brittney S Harrington; Linh Hellmers; Yonghua Sheng; Amy Broomfield; Thomas McGann; Kate Bastick; Laurie Zhong; Andy Wu; Grace Maresh; Shannon McChesney; Kuan Yau Wong; Mark N Adams; Ryan C Sullivan; James S Palmer; Lez J Burke; Adam D Ewing; Xin Zhang; David Margolin; Li Li; Rohan Lourie; Admire Matsika; Bhuvana Srinivasan; Michael A McGuckin; John W Lumley; John D Hooper
Journal:  Oncogene       Date:  2019-08-30       Impact factor: 9.867

10.  An oncogenic viral interferon regulatory factor upregulates CUB domain-containing protein 1 to promote angiogenesis by hijacking transcription factor lymphoid enhancer-binding factor 1 and metastasis suppressor CD82.

Authors:  Wan Li; Qingxia Wang; Xiaoyu Qi; Hongmei Lu; Yuheng Chen; Jiale Shi; Fei Wang; Ziyu Wang; Yao Lu; Zhongmou Lu; Qin Yan; Cong Wang; Shou-Jiang Gao; Chun Lu
Journal:  Cell Death Differ       Date:  2020-06-17       Impact factor: 15.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.